Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | BCL2 | P10415 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5588612 | 0.78 | GABRA1 (0.44) | GABRA1GABRB2ALOX15ALOX12BCL2 | |
| SCHEMBL5587604 | 0.78 | GABRA1 (0.44) | GABRA1GABRB2ALOX15ALOX12BCL2 | |
| SCHEMBL5588364 | 0.78 | GABRA1 (0.44) | GABRA1GABRB2ALOX15ALOX12BCL2 | |
| SCHEMBL5587156 | 0.78 | ALOX15 (0.35) | GABRA1GABRB2ALOX15ALOX12BCL2 | |
| SCHEMBL5588197 | 0.76 | GABRA1 (0.41) | GABRA1GABRB2ELANE | |
| SCHEMBL5588039 | 0.75 | GABRA1 (0.48) | GABRA1GABRB2ALOX15ALOX12CA1 | |
| SCHEMBL5589544 | 0.73 | CA1 (0.40) | GABRA1GABRB2ALOX15ALOX12BCL2 | |
| SCHEMBL5590453 | 0.73 | GABRA1 (0.39) | GABRA1GABRB2BCL2MCL1 | |
| SCHEMBL11806669 | 0.72 | ALOX15 (0.31) | GABRA1GABRB2ALOX15ALOX12 | |
| SCHEMBL17187961 | 0.72 | GABRA1 (0.60) | GABRA1GABRB2ALOX15ALOX12PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | GABRA1 3688/4885GABRB2 3686/4885ALOX15 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.